Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
Last year for us, like all Ukrainians, was a daily test for stability and loyalty to a common idea. We each received a unique experience of restructuring processes and organizing…